2019-06-015 - miRFec - Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer
Acronim & Gínjol codes
miRFec
2019-06-015
Main technology offer
Increased levels of 2 miRNAs and hemoglobin in feces can identify patients with AAs or CRC more accurately than fecal hemoglobin concentration alone
Ownership
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
To reduce the number of unnecessary colonoscopies at the healthcare system and improve sensitivity with respect to current approaches (ie, FIT).
Market Data
There is an emerging need of colorectal cancer screening in the average-risk population. However, current strategies, such as FIT-based screening, have fall due to high false-positive rate, leading to a significant number of unnecessary colonoscopies. On the other, hand, the use of biomarkers as mirFEC is a more sensitive and improved cost/effectiveness strategy.
0
0
0
Validate the better performance of mirFEC in front the most common approach (fecal immunochemical testing, FIT) in clinical studies. Next, negotiate with Eiken a license agremeent
More sensitive and improved cost/effectiveness strategy to screen colorectal cancer in average-risk population
Screening of average-risk individuals
Funding
Not applicable
Not applicable
1. Validating the miRFec test in a multicentric study (phase 1 to establish miRFec score cut-off); 2. Validating the mirFec in a multicentric study (phase 2 to compare results with FIT); 3. License the technology to Eiken
Technology Status
A more sensitive/cost-effective kit for the detection of colorectal cancer
Need a partner to implement the mirFEC technology into their KIT
The mirFEC is currently being validated in a multicentric Study, currently the proposal for a Phase II study is being negotiated. Afterwards, the technology should be licensed to Eiken who will lead the next steps.
National phase in; - Australia P5516AU00; Japó; P5516JP00; Nova Zelanda; P5516NZ - Estats Units; P5516US00; Europa; PCT/EP2020/069918
Eiken is an international company dedicated to sell diagnostic test. Eiken has funded mirFEC project throught several donations and a Research and Cooperation Agreement. This agreement includes a first-right to negotiate a technology license agreement.
Additional information
Increased levels of 2 miRNAs and hemoglobin in feces can identify patients with AAs or CRC more accurately than fecal hemoglobin concentration alone